

Investment Opportunity in series B funding

**The Company**Corporis Medical is a medical device company which started its operations in 2015, focusing on minimizing post-operative complications with smarter surgical tools i.e. MEDICLOSE**TM** and LAPRIXA**TM**. Furthermore, Corporis Medical is developing innovative solutions for improving access, closure and diagnostic measurements for minimally invasive interventional procedures.

The company has several products in development in collaboration with a network of partners (KOL, designers; suppliers; distributors)

**Products/Technology**  
The company focuses on developing laparoscopic devices to automatically close trocar induced wounds and to measure the blood pressure of organs tissue providing a tissue/brachial index (TBI) an early indicator for proper perfusion and wound healing. More interventions have been done with the prospect in the development for faster and user friendly suturing of vascular large-bore access wounds, a rapidly growing field in interventional cardiology and vascular surgeries. These interventions have been done to decrease the number of second surgeries, future complications, to save time, and to decrease costs.

**Advantage**  
MEDICLOSE**TM** reduces time to close trocar induced wounds and the risk of a herniation of the wound. LAPRIXA**TM** blood pressure device measures blood pressure within 20-30 sec and saves lives by providing an unique and objective wound heal indicator (TBI) and reducing the number of unwanted complications like anastomotic leakages and secondary interventions.

**The Market Opportunities**The target markets are hospitals, clinics and health care providers worldwide who would want to use the laparoscopic medical devices for their surgeries to decrease complications and reduce costs of treatment. With a total market of 10 million laparoscopic procedures yearly Corporis Medical could save thousands of lives with their new laparoscopic interventions.

**Focus for Series B funding**

Corporis medical is raising € 3- 5 M in equity and loans to finance the next phase of the company with a focus on clinical assessment and product launch of its leading products MEDICLOSE**TM** and LAPRIXA**TM** and create partnerships with key players in sales and distribution. Funds will also be used to strengthen its product pipeline and company structure as an integrated medical device company.

*John Marugg CEO & Xander Veenhof CSO*

|  |  |
| --- | --- |
| Year to date Milestones 2020 | |
| Funding | Pre-seed 600 K (2015)  Series A (2018/2020) at €1.6 million Plus non dilutives 3.5 M |
| Patents | 4 patent families |
| Trade Marks | MEDICLOSE**TM** and LAPRIXA**TM** |
| QA - QMS  Regulatory | ISO13485 certified  MEDICLOSE**TM** class 3  LAPRIXA**TM** Class 2a device |
| Focus 2020 | Clinical assessment |
| First in man | Supply to hospitals |
| MEDICLOSETM & LAPRIXATM | Manufacturing and Supply Chain in place |
| M&S activities | First sales |

|  |  |
| --- | --- |
| Key Value Drivers 2020-2025 | |
| MEDICLOSE TM | First in Man (FIM): 2020 CE & start Sales: 2021 |
| LAPRIXATM | FIM: 2021  CE mark and start sales: 2022 |
| US FIM & Product launch  Co-development US-FDA registration | MEDICLOSE**TM**: 2022  LAPRIXA**TM**: 2023 Follow 510K predicate |
| Distribution | EU and ROW; US trough co-development partner. |
| Product pipeline | LAPRIXA**TM** new applications  Radial Stapler device |
| Location HQ  R&D and Buss dev. | MHC campus, Maastricht, Netherlands |

|  |  |
| --- | --- |
| Series B round : Fees and Costs | |
| Funding required | €3 - 5 million  Closing at > 3 M equity |
| Investor profile | Investment Funds; Institutional and corporate VC |
| Closing costs | 1% for investors |
| Revenue | From €50K to € 3 million in 2023 |
| NPV (20% Discount): | € 30 M |
| Exit | Trade sale to strategic investor(s) in part or all in 2023 |

|  |  |
| --- | --- |
| Contact Details | |
| Corporis Medical  Oxfordlaan 55  6229 EV Maastricht | +31 43 388 2948  John.marugg@corporis-medical.com |